Among these, mutations in TP53, APC, KRAS, BRAF, and ATM covered 97.55% of the TCGA population and 83.02% of the validated CRC patients, which were shown to be associated with the development of CRC and can be used as diagnostic features (94). Here, TP53 is linked to colorectal carcinoma.